Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Consistent Dividend Stocks to Buy Now. Eli Lilly (LLY)'s Pharmaceutical Leadership as a Driver of Consistent Dividends Eli Lilly and Company (NYSE:LLY) is an Indiana-based multinational pharmaceutical company. Analysts expect the company to remain a leader in the rapidly expanding weight-loss market at least through the end of the decade. Its drug tirzepatide, marketed as Mounjaro and Zepbound for diabetes and obesity, is projected to generat ...

Core Viewpoint - Viking Therapeutics experienced a significant stock drop of nearly 44%, marking its largest intraday decline since April 2016, following disappointing mid-term trial data for its oral weight loss drug VK2735 [2][5]. Group 1: Viking Therapeutics - The mid-term trial data for VK2735 indicated that patients could lose up to 12.2% of their weight, with 80% of participants reporting a weight loss exceeding 10% [5]. - However, approximately 28% of patients withdrew from the trial within three months, raising concerns about the drug's competitiveness against offerings from Eli Lilly and Novo Nordisk [6]. - In contrast, last year, Viking Therapeutics reported positive results from the second phase of VK2735 trials, where patients on weekly doses lost an average of 14.7% of their weight after 13 weeks [6]. Group 2: Eli Lilly - Eli Lilly's oral weight loss drug Orforglipron showed positive results in its phase three clinical trial, with participants losing an average of 12.4 kg (approximately 12.4%) after 72 weeks [9]. - Following the announcement of Orforglipron's results, Eli Lilly's stock fell over 14%, resulting in a market cap loss of about $100 billion [10]. - Despite the initial drop, analysts believe the sell-off was an overreaction, as Eli Lilly's core growth drivers remain strong, and Orforglipron has significant global market potential [10].

整理 | GLP1减重宝典内容团队 ▍GLP-1减肥神药，拟被纳入美国医保 8月1日，据外媒报道，特朗普政府正筹备一项试点计划，允许联邦医保（Medicare）和低收入人群医疗补助（Medicaid）覆盖减重药物费用， 目标是通过扩大对GLP-1类药物的可及性，缓解美国日益严重的肥胖问题。 这一举措基于拜登政府在2024年卸任前提出的初步方案。根据《华盛顿邮报》获得的美国医保与医疗补助服务中心（CMS）文件，该试点项目 将允许各州Medicaid和Medicare 的GLP-1药物提供"体重管理"用途的报销支持。 GLP-1类药物最初用于治疗2型糖尿病，因其能够通过抑制食欲、减缓胃排空等机制显著降低体重，近年来被广泛用于肥胖干预。但其高昂费用 （年均约5,000至7,000美元）引发了有关财政可持续性的担忧。 该举措也可能引发政府内部意见分歧。CMS负责人、曾公开支持GLP-1类药物的Mehmet Oz，与对其成本和依赖性提出批评的卫生部长小罗伯 特·F·肯尼迪立场并不一致，后者强调药物不能取代健康的生活方式。 目前， 包括司美格鲁肽（Ozempic、Wegovy）与替尔泊肽（Mounjaro、Zepboun ...